The May 2020 edition of Milk Manager News is now available to download and read on the FAS website.… https://t.co/xw5xtCONdH
RT @SimonBatesUK: Now. This I think is very impressive
RT @CasMillar: Are you dreaming of a post lockdown couples escape? We are now taking LOCKDOWN DREAMING bookings, pay NO money now, lock in…
The company has been given the go-ahead by the Veterinary Medicines Directorate (VMD) to market its Finadyne Transdermal non-steroidal, anti-inflammatory pour-on as a treatment for reducing pyrexia linked to acute mastitis.
MSD was previously granted a licence allowing it to claim the product is efficient in reducing pyrexia – a fever or abnormal increase in body temperature – associated with bovine respiratory disease (BRD).
It can now also claim the product – the first of its kind to treat animals – is effective in treating pyrexia related to acute mastitis.
Dr Martin Behr, technical manager at MSD Animal Health, said the latest licence gave veterinary surgeons and farmers a new option in the treatment of mastitis.
He added that cattle farmers who opted for the pour-on over injections could reduce the time it took them to treat cattle by more than 60%.
It would also reduce the stress experienced by cattle when restrained, he said.
“The single pour-on application means less stress for the animal, and milk from lactating cows can go back in the tank in just 36 hours. In addition, use of a pour-on NSAID means reduced use of needles and better animal well-being.”
(Farmers Weekly 18th May, 2016)